Synaffix Wins ‘Greatest ADC Platform Expertise’ Award Once more at World ADC Awards Ceremony 2022
3 min read
AMSTERDAM, Sept. 15, 2022 /PRNewswire/ — Synaffix B.V., a biotechnology firm targeted on commercializing its clinical-stage platform know-how for the event of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, at this time pronounces that the Firm was awarded ‘Greatest ADC Platform Expertise’ on the World ADC Convention 2022.
This marks the second time that Synaffix’ groundbreaking ADC platform know-how has been acknowledged as industry-leading by successful 1st place on this award class. The 2022 World ADC Awards finalists have been shortlisted by way of a voting pool of over 2,500 people, with a panel of distinguished, impartial world-renowned ADC consultants assessing every finalist to determine the winners.
Synaffix’ proprietary ADC know-how platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ applied sciences. These applied sciences are geared toward enabling best-in-class ADCs from any antibody, with considerably enhanced efficacy and tolerability.
Prof. Floris van Delft, CSO of Synaffix, mentioned: “We’re thrilled to have gained the ‘Greatest ADC Expertise Platform’ Award once more. This appreciation proven by our {industry} friends is testomony to the creativity and expertise of our scientific crew that has developed our proprietary best-in-class ADC platform. It is unbelievable to see that our know-how is now getting used to develop 18 totally different focused most cancers therapeutics throughout 10 collaborations with top-tier biotech and pharma firms, probably main to higher cures for most cancers sufferers. We’d not be at this stage with out our companions and are very grateful for his or her continued belief and help.”
About Synaffix B.V.
Synaffix B.V. is a biotechnology firm that allows ADC product candidates utilizing its clinical-stage, site-specific ADC know-how platform primarily based on GlycoConnect™, HydraSpace™ and toxSYN™, that collectively allow any firm with an antibody to develop proprietary best-in-class ADC merchandise below a single license from Synaffix.
The Synaffix platform permits a fast timeline to clinic as a result of established provide chain of know-how elements. Granted patents masking Synaffix’ know-how present end-to-end safety of the manufacturing know-how in addition to the ensuing merchandise by way of not less than 2035. The enterprise mannequin of Synaffix is target-specific know-how out-licensing, as exemplified by way of its current offers with ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics and Emergence Therapeutics.
Synaffix is backed by a prime tier, life science-focused investor syndicate that features Aravis, BioGeneration Ventures, BOM Capital and M Ventures.
For extra data, please go to the web site at www.synaffix.com.
About The Synaffix ADC Platform Expertise
Synaffix’ proprietary ADC know-how platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ applied sciences. These applied sciences are geared toward enabling best-in-class ADCs from any antibody, with considerably enhanced efficacy and tolerability.
GlycoConnect™ is a clinical-stage conjugation know-how that exploits the native antibody glycan for site-specific and steady payload attachment and is tunable to DAR1, DAR2 or DAR4 codecs. HydraSpace™ is a clinical-stage compact and extremely polar spacer know-how that’s designed to additional improve therapeutic index, notably with hydrophobic payloads. toxSYN™ is a linker-payload platform that spans key, validated MOAs for ADC product improvement, together with SYNtecan E™ and SYNeamicin G™, amongst different linker-payloads.
The mix of those three applied sciences offers builders with a “one cease” and easy-to-use ADC know-how platform, permitting any antibody developer to develop its personal proprietary ADC and any ADC developer to develop its pipeline additional and improve its aggressive place.
SOURCE Synaffix
